May 6 2010
Cytori Therapeutics (NASDAQ:CYTX) is reporting its first quarter financial results. More information on our commercial and clinical progress is posted online in the 'May 2010 Shareholder Letter' at http://ir.cytoritx.com.
Key accomplishments for Cytori in the first quarter and year-to-date include the following:
- Continued growth in Celution® and StemSource® System and consumables sales
- Sale and installation of a StemSource® Cell Bank in Japan
- FDA clearance (Q1) and US launch (Q2) of the PureGraft™ autologous fat grafting system
- Gained further clarity from the FDA on US regulatory pathway for the Celution® System
Systems and Consumables
In the first quarter of 2010, Cytori increased its cumulative number of 'revenue systems' (those sold directly to physicians, distributors or placed, which are generating consumable sales) to 110, compared to 59 at the end of the first quarter of 2009 and 101 at the end of the prior quarter.
In addition, 342 consumables were shipped in the first quarter of 2010, compared to 337 consumables shipped in the fourth quarter of 2009 and 241 consumables shipped in the first quarter of 2009. Of these, 261 consumables were re-orders in the first quarter of 2010, compared to 164 re-orders in the same quarter of 2009 and 258 re-orders in the prior quarter. More than 2,300 cumulative consumables have been shipped to date since commercialization began in Q1 2008.
Financials
Total revenues for the first quarter of 2010 were $4.4 million, which consisted of $2.3 million in product revenue from Celution® and StemSource® sales in Europe, Asia and the United States and $2.1 million in development revenue. This compares to $1.9 million in total revenues in the first quarter of 2009, of which all $1.9 million were attributable to product sales. Gross margin was 59% with a gross profit of $1.3 million, up from 43% with a gross profit of $0.8 million in the first quarter of 2009.
Total operating expenses were $5.6 million, compared to $6.4 million in the first quarter of 2009. Included in operating expenses was a $1.9 million net reduction in non-cash change in fair value of the warrant and option liability compared to a $0.8 million net reduction in the first quarter of 2009.
Cytori ended the quarter with $22.7 million in cash and cash equivalents plus $2.7 million in accounts receivable, net. Subsequent to end of the quarter, Cytori raised an additional $2.3 million from scheduled sales of its common stock under its current financing arrangement with Seaside 88, LP.
SOURCE Cytori